Extended Data Fig. 10: EBV and SARS-CoV-2 ELISpot in COVID-19 cancer patients.
From: CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
ELISpot was performed after stimulation of PBMC with no peptide, EBV, and SARS-CoV-2 peptide pools. a, IFN-γ (No Peptide vs. COVID, p = 0.003) and IL-2 (No Peptide vs. COVID, p = 0.03; EBV vs. COVID, p = 0.02) spot forming units (SFU) per million PBMC in heme cancer patients (n = 13). Significance determined by Wilcoxon test. b, IFN-γ SFU per million PBMC in heme cancer patients treated with (n = 8) and without (n = 5) αCD20 with no-peptide background condition subtracted. c, IFN-γ and IL-2 SFU between solid (n = 10) and heme (n = 13) cancer patients. Simple linear regression between IFN-γ SFU per million cells and percent activated CD4 (d) and CD8 (e) T cells in alive (n = 8) and dead (n = 5) heme cancer patients. (All) Significance determined by two-sided Mann Whitney test. *p < 0.05, **p < 0.01. Median and 95% CI shown.
